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Abstract
Background: Scleroderma is a systemic autoimmune disease characterized mainly by skin manifestations and
involvement of various visceral organs, especially the lungs. Lung involvement is the leading cause of mortality in
patients with scleroderma. There are data to suggest that cyclophosphamide (CYC) and mycophenolate mofetil
(MMF) are effective in the management of scleroderma interstitial lung disease (SSc-ILD) but no head to head
comparative data are available to date.
Methods: For the last 3 years, patients with SSc-ILD have been treated at our centre by protocol-based administration
of intravenous CYC and MMF. Results of lung function tests (spirometry) were recorded at baseline, 3 months and
6 months in every patient. The clinical records of patients with systemic sclerosis and significant ILD, who were not
previously exposed to any immunosuppressant and were treated with MMF OR CYC, were reviewed. The efficacy of
treatment was assessed by the change in forced vital capacity on spirometry.
Results: Of the total 57 patients included in the analysis, 34 were treated with MMF and 23 were treated with
CYC. Mean duration of illness was 4.19 ± 2.82 years in the MMF and 6.04 ± 5.96 years in the CYC group. After
6 months of therapy, FVC increased by 10.84 ± 13.81 % in the CYC group and by 6.07 ± 11.92 % in the MMF
group. This improvement from baseline was statistically significant in both groups (P < 0.01). The improvement
was comparable with no statistically significant differences between groups (P = 0.373). There were no major
adverse events reported in either arm.
Conclusion: Both MMF and CYC were equally effective in stabilizing lung function in patients with scleroderma and ILD.
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Background
Lung diseases in scleroderma (SSc) are the leading dis-
ease-related cause of mortality, most typically including
interstitial lung disease (ILD) and/or pulmonary arterial
hypertension (PAH) [1]. Approximately 80 % of patients
have evidence of pulmonary fibrosis at postmortem exam-
ination [2] or on high-resolution computed tomography
(HRCT), although clinically evident disease is present only
in approximately 40 % of patients [3]. The 10-year survival
rates of patients with SSc in an Italian study involving
915 patients was 64.9 % in those with lung involvement
in comparison to 80.6 % in those without lung involve-
ment [4].
For more than 15 years, cyclophosphamide (CYC) is
used in the treatment of SSc-ILD. CYC is a cytotoxic
immunosuppressive agent that suppresses lymphokine
production and modulates lymphocyte function by al-
kylating various cellular constituents and depressing
the inflammatory response via normalization of neutro-
philia and healing of vascular endothelial cells [5]. CYC
is the only agent shown to at least stabilize lung func-
tion in a randomized, controlled trial [6].
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Mycophenolic acid, the active metabolite of mycophe-
nolate mofetil (MMF) and mycophenolate sodium (MS),
inhibits inosine monophosphate dehydrogenase and de-
pletes guanosine nucleotides. It is thus thought to decrease
the activity of inflammatory cells and to produce anti-
fibrotic and immunomodulatory effects. Mycophenolic
acid has emerged recently as a promising therapy for
SSc [7]. Evidence supporting its use derives from small,
uncontrolled, single-arm studies, suggesting that myco-
phenolate is a safe therapeutic modality associated with
functional stabilization of SSc-ILD [8–15].
No head to head data comparing the efficacy of CYC
and MMF are available to date. The objective of the
study was to compare the efficacy of MMF and CYC in
patients with SSc-ILD for improvement in lung function.
Methods
Study design
A single-centre, retrospective study
Patients and treatment regimes At our centre MMF
and CYC were used, in a protocol-based manner, for the
treatment of SSc-ILD. MMF was initiated with 500 mg
once a day and was increased to maximum tolerable
dose or to a maximum dose of 3 g daily. Patients were
advised to take MMF 30 minutes before food or 2 h after
food. The starting dose of CYC was 600 mg/m2 given as
an intravenous (IV) infusion. Six monthly pulses of CYC
were given and the dose was increased to 1.2 g as toler-
ated. Adequate hydration was maintained. Selection of
the drug for induction therapy was based on the patient’s
willingness to receive a particular drug after explaining
the side effects and treatment costs of each of the drugs in
detail to the patient. After detailed baseline evaluations
every patient underwent a monthly clinical examination.
Forced vital capacity (FVC) was assessed by spirometry at
baseline, 3 and 6 months.
We carried out a retrospective analysis of clinical records
of the patients attending the rheumatology outpatient de-
partment (OPD), who had ILD and had undergone treat-
ment with intravenous pulses of CYC or MMF in the last
3 years. Patients were included for analysis if they were
over 18 years of age, fulfilled the American College of
Rheumatology (ACR) 2013 classification criteria for SSc
with significant ILD as defined by FVC ≤80, and had evi-
dence of ILD on thoracic HRCT. Patients were excluded if
they had end-stage lung disease and FVC <20 % and were
oxygen dependent, clinically significant abnormalities on
HRCT that were not attributable to SSc, clinically signifi-
cant cytopoenia (Hb <10 g %, leucocyte count <4000 per
cubic millimeter, platelet count <1,50000 per cubic milli-
meter), altered liver function on tests (liver enzymes >2
times normal and/or bilirubin >1.5 times the upper limit of
normal) or altered renal function (unexplained haematuria
or serum creatinine >2.0 mg/dl), or who had already been
treated with CYC or MMF or other immunosuppressants
such as cyclosporin or rituximab, or had severe cardiac dis-
ease, with moderate to severe PAH (right ventricle systolic
pressure (RVSP) >50 mm Hg) measured by transthoracic
echocardiography (TTE), or were chronic smokers, or were
pregnant or lactating. Those patients who were unable to
perform spirometry or whose data were missing were not
included in the study.
The study was performed in accordance with the Dec-
laration of Helsinki and received approval from the insti-
tutional ethics committee of Amrita institute of medical
science and research institute. Informed consent was not
relevant as it was a retrospective study.
Lung function test
Spirometry (MicroQuark-Cosmed PFT suit) was per-
formed by a highly trained and experienced technician
in all the patients so as to minimize interobserver variabil-
ity to achieve a high degree of reproducibility (interclass
correlation coefficient of 0.96). The results were expressed
as percentage of predicted for each patient. Depending on
the FVC values, the severity of ILD was classified as mild
(70–80 %), moderate (50–69 %) and severe (<50 % pre-
dicted values) according to Medsger’s severity scale [16]. In
order to evaluate the response to treatment by means of
spirometry values, the recommendations of the American
Thoracic Society (ATS) [17] were followed. According
to these recommendations, improvement is defined by
an increase in FVC ≥10 %, stabilization by change in
FVC <10 % and worsening by a reduction in FVC ≥10 %.
Spirometry was carried out in all patients at baseline (be-
fore treatment was started) and repeated at 3 and 6 months.
Baseline and 6-month data were used for comparisons.
Statistical analysis
Data were presented as mean ± standard deviation for
numerical variables. Continuous variables were analysed
within groups using the paired t test, and the independent
two-sample t test or the Mann–Whitney test (non-parametric
data) was used to compare variables in the two groups.
The chi square test was used to test the associations be-
tween categorical variables. Differences were considered
significant at P ≤ 0.05. Data were analysed using IBM SPSS
Version 20 software.
Results
As summarized in Table 1, both groups were comparable
in terms of demographic data and other baseline vari-
ables. There were 23 patients with SSC-ILD (18 female
and 5 male) in the CYC group and 34 patients (31 female
and 3 male) in the MMF group. The mean age was
around 46 years in both groups. The mean disease dur-
ation, defined as the time from initiation of the first
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non- Raynaud’s symptom, was around 5 years. During the
study period 17 patients in the CYC and 30 patients in the
MMF group were on low-dose steroids (≤5 mg/day). The
average cumulative dose of CYC was 7.2 g and the average
maximum dose of MMF was 2.62 g/day.
Both the groups had similar lung function at baseline
as evidenced by a baseline FVC of 48.74 ± 15.67 % in the
CYC group and 53.44 ± 13.69 % in the MMF group.
PAH was detected in two patients in the CYC group and
four patients in the MMF group.
As shown in Fig. 1, the mean FVC increased to 55.99 ±
13.47 % from the baseline value of 53.44 ± 13.69 % in the
MMF group (P = 0.003). Similarly, mean FVC improved to
53.09 ± 14.93 % from the baseline value of 48.74 ± 15.67 %
(P = 0.003) in the CYC group. The mean percentage in-
crease in FVC at 6 months compared to baseline was
10.84 ± 13.81 % in the CYC group and 6.07 ± 11.92 % in
the MMF group. Both improvements were statistically
significant when compared to baseline. Hence, as per
the ATS recommendation, the CYC group had an im-
provement, as the percentage increase in FVC was >10 %,
but FVC was only stabilized in the MMF group (FVC
change <10 %). When the change in FVC at 6 months was
compared in the two groups, there was no significant dif-
ference (P = 0.232). As shown in Fig. 2, when numerical
values were considered, 68.57 %, 28.57 % and 2.85 % of
patients in the CYC group had increased, decreased and
unchanged percentage FVC, respectively, and 78.26 %,
Table 1 Demographic and baseline clinical characteristics of patients in the cyclophosphamide (CYC) and mycophenolate mofetil
(MMF) groups
Characteristics CYC (n = 23) MMF (n = 34) P value for significance
Age, mean ± SD 46 ± 10.34 45.24 ± 13.87 0.82
Female, n (%) 18 (78.2) 31 (91.18) 0.24
Disease duration in years, mean ± SD 6.04 ± 5.96 4.19 ± 2.82 0.11
Clinical features, n (%)
Breathlessness 21 (91.3) 30 (88.2) 0.53
Arthritis 23 (100) 28 (82.4) 0.07
Skin changes 21 (91.3) 30 (88.2) 0.53
Raynaud’s symptoms 17 (74) 18 (52.9) 0.16
Baseline FVC %, mean ± SD 48.74 ± 15.67 53.44 ± 13.69 0.23
Pulmonary artery hypertension, n (%) 2 (2.7) 4 (11.8) 0.63
Anti-scl-70-positive, n (%) 12 (52.17) 16 (47.18) 0.41
FVC forced vital capacity
Fig. 1 Mean change in percentage forced vital capacity (FVC) at baseline and 6 months in the mycophenolate mofetil (MMF) and cyclophosphamide
(CYC) groups
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17.39 % and 4.35 % of patients in the MMF group had in-
creased, decreased and unchanged percentage FVC after
6 months of treatment.
Both drugs were generally well tolerated in all patients
except for nine patients in the CYC group and four pa-
tients in the MMF group who developed lower respira-
tory tract infection; this was treated with a short course
of antibiotics. No exacerbation of ILD, hospital admissions,
or fatalities occurred in either group during treatment.
Discussion
The results of this retrospective analysis demonstrate
that both CYC and MMF were equally effective in pre-
serving lung function in patients with SSc-ILD. Pre-
vention of disease progression is considered the most
important aim in SSc-ILD [18].
In a landmark study, The Scleroderma Lung Study Re-
search Group noted that oral CYC achieved a modest
but significant beneficial effect on lung function and pa-
tients’ quality of life, but unfortunately, it also provoked
a serious adverse event in six patients [6]. After the first
year these patients were observed without any immuno-
suppression and by 2 years the improvement in lung
function that had been observed in the CYC arm was
lost [19]. The modest and transitory benefit of CYC in
patients with SSc-ILD and the substantial toxicity of the
drug compels us to search for safer alternatives, espe-
cially for younger patients with mild disease, who would
benefit from longitudinal administration of therapeutic
modalities with minimal side effects, and to reserve more
aggressive and potentially more beneficial cytotoxic
regimens for later stages of the disease course.
To date, all the available information on the use of
mycophenolate in the treatment of SSc-related ILD
comes from small-scale, single-arm and open-label stud-
ies. A recent meta-analysis, which includes six studies and
a total of 69 patients, the majority of whom had diffuse
cutaneous SSc-related ILD, confirmed the acceptable
safety and tolerability profile of mycophenolate. In the
primary analysis, four out of six studies reported statistically
significant functional improvement following 12-month
oral administration of MMF or MS, and the remaining
two studies reported stabilization of disease; however, a
pooled analysis did not corroborate this finding. In par-
ticular, in the overall analysis of 69 patients, MMF or
MS treatment was not associated with a statistically sig-
nificant beneficial functional effect as assessed by both
FVC and the diffusing capacity of the lungs for carbon
monoxide (DLCO) [20]. A more recent, study by Fischer
et al. [9], including 125 patients with connective tissue
disease-associated ILD (of whom 44 patients had SSc-
ILD) treated with mycophenolate for a median of
897 days, showed stabilization or improvement of lung
function.
The results of the current study show both MMF and
CYC were not only able to stabilize lung function but
also there was a numerical increase in FVC in the major-
ity of patients. In view of the expected annual decline in
lung function over time among patients with SSc-ILD
[21], it is reasonable to state that a marginal increase in
FVC or even a stabilization of functional status through
the disease course is a great achievement, especially
when the therapeutic agent used presents with an excel-
lent safety profile tested longitudinally.
Fig. 2 Change from baseline in percentage forced vital capacity (FVC%) at 6 months in the mycophenolate mofetil (MMF) and cyclophosphamide
(CYC) groups: 68.57 %, 28.57 % and 2.85 % of patients in the CYC group had increased, decreased and unchanged FVC% respectively, and 78.26 %,
17.39 % and 4.35 % of patients in the MMF group had increased, decreased and unchanged FVC% after 6 months of treatment
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Besides this, it is important to note that in our study
the enrolled patients had a mean disease duration of
around 5 years with moderate to severe ILD prior to ad-
ministration of CYC or MMF. It can be argued that
stabilization can happen in a group of patients with SSc
and the results of the study merely reflect the natural
course of disease. But to prove this point we need a pla-
cebo arm, which appears to be unethical in a deadly
disease like SSc-ILD. Moreover, improvement in lung
function is not part of the natural course of the disease
and the patients with FVC <70 % are more likely to de-
teriorate than others. Scleroderma lung study 2 (SLS2),
the results of which are currently available in abstract
form, compared oral cyclophosphamide with MMF.
The results showed that the improvement in FVC is
comparable in both the arms at the end of 2 years.
These results are in concurrence with ours, although in
SLS 2 oral CYC was used instead of IV CYC.
Our study is limited by the lack of a control arm for
those who were not treated, randomization and long fol-
low up. The 6-minute walking test was not used as an
outcome measure as it has been proven that features like
pain and musculoskeletal involvement can influence the
result [22], and HRCT could not be performed in all pa-
tients at 6 months due to financial constraints. As the
reproducibility of FVC is better than that of DLCO and
DLCO is less specific than FVC for lung function,
DLCO was not chosen as an outcome measure.
Conclusion
We support the use of immunosuppressants in patients
with scleroderma ILD. Although MMF and CYC may be
equally effective, MMF may be preferred due to the
long-term toxicity of CYC. Larger randomized controlled
studies are sorely needed to support this premise.
Abbreviations
ACR: American college of rheumatology; ATS: American Thoracic Society;
CYC: cyclophosphamide; DLCO: diffusing capacity of the lungs for carbon
monoxide; FVC: forced vital capacity; HRCT: high-resolution computed
tomography; ILD: interstitial lung disease; IV: intravenous;
MMF: mycophenolate mofetil; MS: mycophenolate sodium; PAH: pulmonary
arterial hypertension; RVSP: right ventricle systolic pressure;
SLS2: Scleroderma lung study 2; SSc: scleroderma; SSc-ILD: scleroderma
interstitial lung disease; TTE: transthoracic echocardiography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PDS designed the study and gave his valuable comments while drafting
this article. MB, KN, SSu and SSr collected the data and drafted the article.
All authors approved the final version to be submitted for publication.
Acknowledgements
The authors are thankful to Ms Prasanna (PFT-spirometry technician)
Pulmonology department and Mr Unnikrishnan (Statistician), Amrita
institute of medical science, Kochi, for their valuable contribution in
performing spirometry and data calculation, respectively. The authors are
also thankful to Dr Nishant Bhimani (Resident-community medicine, C.U.
Shah medical college Surendranagar) for his valuable comments in the
statistical analysis of the study.
Author details
1Centre For Arthritis & Rheumatism Excellence (CARE), NH-47, Nettoor, Kochi,
Kerala 682040, India. 2Department of Rheumatology, Amrita Institute of
Medical Sciences, Ponekkara, Kochi, Kerala, India. 3Department of Medicine,
Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India.
Received: 5 January 2016 Accepted: 9 May 2016
References
1. Taylor J, Bolster M. Bronchiolitis obliterans with organizing pneumonia
associated with scleroderma and scleroderma spectrum diseases. J Clin
Rheumatol. 2003;9(4):239–45.
2. D’Angelo W, Fries J, Masi A, Shulman L. Pathologic observations in systemic
sclerosis (scleroderma). Am J Med. 1969;46(3):428–40.
3. Todd N, Lavania S, Park M, Iacono A, Franks T, Galvin J, et al. Variable
prevalence of pulmonary hypertension in patients with advanced interstitial
pneumonia. J Heart Lung Transplant. 2010;29(2):188–94.
4. Ferri C, Valentini G, Cozzi F, Sebastini M, Michelassi C, La Montagna G, et al.
Systemic sclerosis. Medicine. 2002;81(2):139–53.
5. Simeon-Aznar C, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O’ Callaghan A,
Solans-Laqué R, Palliza E, et al. Intravenous cyclophosphamide pulse therapy
in the treatment of systemic sclerosis-related interstitial lung disease: a long
term study. TORMJ. 2008;2(1):39–45.
6. Tashkin D, Elashoff R, Clements P, Goldin J, Roth M, Furst D, et al.
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J
Med. 2006;354(25):2655–66.
7. Nihtyanova S, Brough G, Black C, Denton C. Mycophenolate mofetil in
diffuse cutaneous systemic sclerosis–a retrospective analysis. Rheumatology.
2007;46(3):442–5.
8. Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al.
Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-
associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:
143637. doi:10.1155/2012/143637.
9. Fischer A, Brown K, Du Bois R, Frankel S, Cosgrove G, Fernandez-Perez E,
et al. Mycophenolate mofetil improves lung function in connective tissue
disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.
10. Gerbino A, Goss C, Molitor JA. Effect of mycophenolate mofetil on pulmonary
function in scleroderma-associated interstitial lung disease. Chest.
2008;133(2):455–60.
11. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas L. Mycophenolate
mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol.
2010;29(10):1167–8.
12. Liossis S, Bounas A, Andonopoulos A. Mycophenolate mofetil as first-line
treatment improves clinically evident early scleroderma lung disease.
Rheumatology. 2006;45(8):1005–8.
13. Swigris J, Olson A, Fischer A, Lynch D, Cosgrove G, Frankel S, et al.
Mycophenolate mofetil is safe, well tolerated, and preserves lung function
in patients with connective tissue disease-related interstitial lung disease.
Chest. 2006;130(1):30–6.
14. Zamora A, Wolters P, Collard H, Connolly M, Elicker B, Webb W, et al. Use of
mycophenolate mofetil to treat scleroderma-associated interstitial lung
disease. Respir Med. 2008;102(1):150–5.
15. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E,
et al. A pilot study of mycophenolate mofetil combined to intravenous
methylprednisolone pulses and oral low-dose glucocorticoids in severe
early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287–92.
16. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W,
et al. Assessment of severity and prognosis in SSc. Clin Exp Rheumatol.
2003;21:S42–6.
17. Collard H, Loyd J, King T, Lancaster L. Current diagnosis and management
of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med.
2007;101(9):2011–6.
18. Antoniou K, Wells A. Scleroderma lung disease: evolving understanding in
light of newer studies. Curr Opin Rheumatol. 2008;20(6):686–91.
19. Tashkin D, Elashoff R, Clements P, Roth M, Furst D, Silver R, et al. Effects of
1-year treatment with cyclophosphamide on outcomes at 2 years in
scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026–34.
Shenoy et al. Arthritis Research & Therapy  (2016) 18:123 Page 5 of 6
20. Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P,
et al. Effect and safety of mycophenolate mofetil or sodium in systemic
sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med.
2012;2012:1–7.
21. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann
Rheum Dis. 2003;62(2):97–9.
22. Khanna D, Seibold J, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic
sclerosis-associated interstitial lung disease: lessons from clinical trials,
outcome measures, and future study design. CRR. 2010;6(2):138–44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shenoy et al. Arthritis Research & Therapy  (2016) 18:123 Page 6 of 6
